ABT-263 induces dose-limiting thrombocytopenia due to platelets requiring BCLXL for survival, and BCL2/BCLXL also regulate monocyte/macrophage and neutrophil survival33,34; we therefore examined the effect of cycles of ABT-263 on blood counts. The gene discussed is BCL2; the disease is Thrombocytopenia.